ES2597835T3 - Proteína asociada a enfermedad - Google Patents

Proteína asociada a enfermedad Download PDF

Info

Publication number
ES2597835T3
ES2597835T3 ES02737923.9T ES02737923T ES2597835T3 ES 2597835 T3 ES2597835 T3 ES 2597835T3 ES 02737923 T ES02737923 T ES 02737923T ES 2597835 T3 ES2597835 T3 ES 2597835T3
Authority
ES
Spain
Prior art keywords
gene
cells
nucleic acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02737923.9T
Other languages
English (en)
Spanish (es)
Inventor
Thierry Leveillard
Saddek Mohand-Said
David Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Université de Strasbourg
Original Assignee
Novartis AG
Université de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Université de Strasbourg filed Critical Novartis AG
Application granted granted Critical
Publication of ES2597835T3 publication Critical patent/ES2597835T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES02737923.9T 2001-04-06 2002-04-05 Proteína asociada a enfermedad Expired - Lifetime ES2597835T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104712 2001-04-06
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (1)

Publication Number Publication Date
ES2597835T3 true ES2597835T3 (es) 2017-01-23

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02737923.9T Expired - Lifetime ES2597835T3 (es) 2001-04-06 2002-04-05 Proteína asociada a enfermedad

Country Status (22)

Country Link
US (6) US7795387B2 (enExample)
EP (1) EP1379657B1 (enExample)
JP (2) JP4370428B2 (enExample)
KR (1) KR100913258B1 (enExample)
CN (1) CN1529753B (enExample)
AU (1) AU2002312794B8 (enExample)
BR (1) BRPI0208870B8 (enExample)
CA (1) CA2443345C (enExample)
CZ (1) CZ305800B6 (enExample)
EC (1) ECSP024345A (enExample)
ES (1) ES2597835T3 (enExample)
FR (1) FR2823221B1 (enExample)
HU (1) HU226307B1 (enExample)
IL (3) IL158013A0 (enExample)
MX (1) MXPA03009114A (enExample)
NO (1) NO331277B1 (enExample)
NZ (1) NZ528376A (enExample)
PL (1) PL213658B1 (enExample)
RU (1) RU2384586C2 (enExample)
SK (1) SK288465B6 (enExample)
WO (1) WO2002081513A2 (enExample)
ZA (1) ZA200307403B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP5748223B2 (ja) * 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
WO2017120294A1 (en) 2016-01-05 2017-07-13 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
KR20260085174A (ko) 2016-10-11 2026-06-08 파마 싱크, 엘엘씨 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질
JP7495756B2 (ja) * 2019-12-09 2024-06-05 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP5748223B2 (ja) 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用

Also Published As

Publication number Publication date
PL213658B1 (pl) 2013-04-30
CN1529753B (zh) 2013-06-12
PL364681A1 (en) 2004-12-13
SK12232003A3 (sk) 2004-03-02
NO20034452L (no) 2003-12-04
BRPI0208870B8 (pt) 2021-05-25
SK288465B6 (sk) 2017-06-02
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06
US7795387B2 (en) 2010-09-14
HUP0303730A2 (en) 2006-02-28
FR2823221A1 (fr) 2002-10-11
EP1379657B1 (en) 2016-08-17
KR20030094317A (ko) 2003-12-11
CZ20032706A3 (cs) 2003-12-17
CA2443345A1 (en) 2002-10-17
RU2003130638A (ru) 2005-04-20
ZA200307403B (en) 2004-04-21
NZ528376A (en) 2005-09-30
US8114849B2 (en) 2012-02-14
NO331277B1 (no) 2011-11-14
JP2005502319A (ja) 2005-01-27
JP4370428B2 (ja) 2009-11-25
IL158013A (en) 2010-12-30
JP4571695B2 (ja) 2010-10-27
IL199316A (en) 2011-01-31
CA2443345C (en) 2012-12-04
US20080004231A1 (en) 2008-01-03
US20040204350A1 (en) 2004-10-14
US20120108523A1 (en) 2012-05-03
IL158013A0 (en) 2004-03-28
MXPA03009114A (es) 2004-11-22
NO20034452D0 (no) 2003-10-03
WO2002081513A2 (en) 2002-10-17
BR0208870A (pt) 2004-04-27
ECSP024345A (es) 2004-06-28
CZ305800B6 (cs) 2016-03-23
BRPI0208870B1 (pt) 2016-01-12
US20090062188A1 (en) 2009-03-05
CN1529753A (zh) 2004-09-15
US8394756B2 (en) 2013-03-12
AU2002312794B8 (en) 2006-01-12
FR2823221B1 (fr) 2004-04-02
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
JP2009232843A (ja) 2009-10-15
EP1379657A2 (en) 2004-01-14
WO2002081513A3 (en) 2003-05-01
KR100913258B1 (ko) 2009-08-21
US20130287738A1 (en) 2013-10-31
AU2002312794B2 (en) 2005-12-01
HU226307B1 (en) 2008-08-28
US8518695B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
JP4571695B2 (ja) 疾患関連タンパク質
ES2284502T3 (es) 22025, una nueva nucleotido ciclico fosfodiesterasa humana.
US9353162B2 (en) Disease-associated proteins
AU2002312794A1 (en) Disease-associated protein
JP2004516024A (ja) Ｃｄ８３発現に影響を及ぼす化合物、前記化合物を含む薬剤組成物及び前記化合物を同定する方法
US6664229B2 (en) Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
US20030144236A1 (en) Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
US6221676B1 (en) DNA encoding human leukotriene C4 synthase, polypeptides and uses therefor
ES2359233T3 (es) Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular.
ES2595388T3 (es) Método para el tratamiento de la glomerulonefritis
HK1061692B (en) Disease-associated protein
JP2005058116A (ja) アポトーシスを誘導するｉｐ３受容体タンパク質の末端切断型変異体